Trials / Completed
CompletedNCT01411800
An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study of Two Oral Formulations of LX1033 in Healthy Human Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacodynamic effects, pharmacokinetics, and safety of two oral formulations (tablet and capsule) of LX1033 in normal healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 250 mg capsule | Two 250 mg capsules will be administered for 500 mg dose |
| DRUG | 250 mg tablets | Two 250 mg tablets will be administered for a 500 mg dose |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2011-10-01
- Completion
- 2012-05-01
- First posted
- 2011-08-08
- Last updated
- 2012-07-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01411800. Inclusion in this directory is not an endorsement.